Park, Haeseong

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Sabari, J. K., Park, H., Tolcher, A. W., Ou, S.-H. I., Garon, E. B., George, B., Janne, P. A., Moody, S. E., Tan, E. Y., Sen, S. K., et al. (2021) · Journal of Clinical Oncology

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 50

A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients

Park, H., Parker, G. L., Boardman, C. H., Morris, M. M., & Smith, T. J. (2011) · Supportive Care in Cancer

Menopause: Health Impacts and TreatmentsCancer survivorship and care

Cited by 31

First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.

Pant, S., Furqan, M., Abdul-Karim, R. M., Chung, V., Devoe, C. E., Johnson, M. L., Leal, A. D., Park, H., Wainberg, Z. A., Welkowsky, E., et al. (2022) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 28

Production of (−)-α-Bisabolol in Metabolically Engineered Saccharomyces Cerevisiae

Kim, T. Y., Park, H., Kim, S.-K., Kim, S.-J., & Park, Y.-C. (2021) · Journal of Biotechnology

Plant biochemistry and biosynthesisMicrobial Metabolic Engineering and Bioproduction

Cited by 23